INSTANTIATION OF PATIENT-SPECIFIC LOGICAL MODELS WITH MULTI-OMICS DATA ALLOWS CLINICAL STRATIFICATION OF PATIENTS




Jonas Béal¹, Arnau Montagud¹, Emmanuel Barillot¹, Laurence Calzone¹
¹Institut Curie, PSL Research University, Mines Paris Tech, Inserm U900, Paris France





ABSTRACT

Logical models of cancer pathways are typically built by mining the literature and they are usually generic as they apply for large cohorts and do not capture the heterogeneity of patient. We present here a novel framework to **tailor logical models to a patient's tumor**. This methodology enables comparisons between the model simulations and the individual clinical data.

Our approach focuses on integrating mutations, copy number alterations (CNA), and expression data to logical models. These **omics data, after appropriate processing, can be incorporated in the model modifying the activity of the node, the initial conditions or the transition rates, as defined in MaBoSS, a tool performing stochastic simulations of logical models. As a first proof of concept, omics data from breast-cancer patients is integrated into several logical models to derive phenotypic outputs that correlate with clinical read-outs such as survival**, with better performances combining both mutations and expression data. All in all, we aim to **combine the mechanistic insights of logical modeling with multi-omics data integration** to provide patient-relevant models to physicians, enabling precision medicine.







CLINICAL ANALYSIS

0.25

0.00

Different logical models and omics data combinations
 Table 1: Logical models survey

ModelsE2F12DrugBreast3CancerPathways4Number of nodes357398Phenotypic outputsEMTProlif. & Apop.Prolif. & Apop.Breast-specificImage: CancerPathways4Breast-specificImage: CancerPathways4

Table 2: METABRIC4 cohort, ~2000 breast-cancer patients

Data types and their use
Mutations
CNA
RNA

Node activity status
✓
✓
✓

Initial states
✓
✓

Transition rates
✓
✓

Different behaviours depending on the model
On average, performance improvement with integration of several data types, i.e. mutations/CNA/RNA

E2F1 Model Outputs **DrugBreast Model Outputs** CancerPathways Model Outputs Simulation Case mut mut + CNA **⊨** RNA mut + RNA mut + CNA + RNA Survival Curves Based on Combined Scores density ability p = 6.67e-130.75 1.00 0.50 0.25 **Apoptosis** density 1.5 → Low P. & Low A. (480 indiv.) → High P. & Low A. (453 indiv.) Low P. & High A. (455 indiv.) — High P. & High A. (478 indiv.)

1.00

Time

0.75

0.50

Proliferation

PERSPECTIVES



Instantiation of cell-line specific models

Implement drug effect predictions modelling drug actions on personalized models

REFERENCES

¹Stoll et al. Bioinformatics. 2017 ²Khan et al. Nat. Commun. (2017) ³Zanudo et al. Cancer Conv. 2013 ⁴Fumia et al, PLoS One. 2017 ⁵Curtis et al. Nature. 2012

